Altium Capital Management’s ADMA Biologics ADMA Stock Holding History

Altium Capital Management’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-1,395,000	Closed	-$23.9M	–	25
2024 Q4	$23.9M	Buy	1,395,000 +35,000	+3%	+$658K	6.79%	1
2024 Q3	$27.2M	Sell	1,360,000 -150,000	-10%	-$2.33M	8%	2
2024 Q2	$16.9M	Sell	1,510,000 -30,000	-2%	-$252K	6.89%	2
2024 Q1	$10.2M	Buy	1,540,000 +445,000	+41%	+$2.43M	4.02%	6
2023 Q4	$4.95M	Sell	1,095,000 -1,628,011	-60%	-$6.02M	3.36%	13
2023 Q3	$9.75M	Buy	2,723,011 +343,011	+14%	+$1.32M	5.08%	7
2023 Q2	$8.78M	Sell	2,380,000 -490,000	-17%	-$1.82M	6.65%	4
2023 Q1	$9.5M	Hold	2,870,000	–	–	5.27%	3
2022 Q4	$11.1M	Sell	2,870,000 -13,710	-0.5%	-$42.3K	5.66%	2
2022 Q3	$7.01M	Sell	2,883,710 -1,116,290	-28%	-$2.68M	2.57%	5
2022 Q2	$7.92M	Buy	4,000,000 +700,000	+21%	+$1.38M	3.17%	3
2022 Q1	$6.04M	Hold	3,300,000	–	–	2.02%	11
2021 Q4	$4.65M	Buy	+3,300,000	New	+$4.34M	1.28%	28

Other funds holding ADMA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Perpetual Ltd Sydney, New South Wales, Australia $7B AUM 19.75% 1-Year Est. Return

Altium Capital Management's ADMA Position: Q1 2025 in Review

Altium Capital Management sold out of ADMA Biologics (ADMA) in Q1 2025, closing a stake of 1,395,000 shares — an estimated $23.9M sold.

Altium Capital Management first reported a position in ADMA in Q4 2021 and held it in 13 quarters. The position peaked at $27.2M in Q3 2024. 347 funds tracked by Wall St. Rank hold ADMA as of Q1 2025.

Altium Capital Management reported no remaining ADMA Biologics position as of Q1 2025 after selling out during the quarter.
Altium Capital Management sold 1,395,000 ADMA Biologics shares in Q1 2025, an estimated $23.9M.
Altium Capital Management first reported a position in ADMA Biologics in Q4 2021 and held it in 13 quarters.
Altium Capital Management's ADMA Biologics position peaked at $27.2M in Q3 2024.
347 funds tracked by Wall St. Rank held ADMA Biologics as of Q1 2025.

Based on Altium Capital Management's 13F filing for Q1 2025, filed 9 May 2025.